INT'L GROUP(SZ:000411)2023-04-28 16:00Financial Performance - The company's operating revenue for 2022 was ¥30,619,257,331.72, representing a 14.55% increase compared to ¥26,730,979,470.50 in 2021 [25]. - The net profit attributable to shareholders for 2022 was ¥212,228,977.95, a 26.47% increase from ¥167,809,938.17 in 2021 [25]. - The net profit after deducting non-recurring gains and losses was ¥200,389,762.63, up 30.87% from ¥153,120,580.84 in 2021 [25]. - The basic earnings per share for 2022 was ¥0.71, an increase of 26.79% from ¥0.56 in 2021 [25]. - The total assets at the end of 2022 were ¥13,163,827,738.71, reflecting a 7.50% increase from ¥12,245,334,519.36 at the end of 2021 [25]. - The company reported a net cash flow from operating activities of ¥391,167,270.63, which is a 19.98% increase compared to ¥326,023,869.96 in 2021 [25]. - The total operating revenue for 2022 reached ¥30,619,257,331.72, representing a year-on-year increase of 14.55% compared to ¥26,730,979,470.50 in 2021 [65]. - The pharmaceutical wholesale sector generated ¥28,239,776,855.27, accounting for 92.23% of total revenue, with a year-on-year growth of 15.23% [65]. - The sales of medical devices and consumables increased significantly by 48.36%, reaching ¥1,799,420,204.91, which constitutes 5.88% of total revenue [67]. - The company reported a total sales volume of ¥3,047,370,000.00 in 2022, marking a 14.69% increase from ¥2,657,048,000.00 in 2021 [68]. Dividend Distribution - The company plans to distribute a total cash dividend of 63.7 million CNY to all shareholders based on the total share capital on the equity registration date for the 2022 dividend distribution plan [5]. - The cash dividend per 10 shares is set at 1.26 yuan, based on a total share capital of 505,445,173 shares [161]. - The company’s profit available for distribution to shareholders was 102.3 million yuan [159]. - The company plans to maintain a cash distribution total of 63.7 million yuan, adjusting the per-share distribution based on the total share capital at the time of the dividend distribution [161]. - The company’s cash dividend policy has not been adjusted or changed during the reporting period [159]. Market and Industry Insights - The pharmaceutical market in China saw a total sales amount of ¥20,048 billion in the first three quarters of 2022, with a year-on-year growth of 5.67% [36]. - The retail market for pharmaceuticals reached ¥4,337 billion in 2022, with a year-on-year growth of 8.87% [36]. - The pharmaceutical distribution industry is experiencing increased concentration, with leading companies enhancing their market share through innovative services and expanding into new retail and medical device sectors, maintaining growth above the industry average [37]. - The company has achieved full coverage of public medical institutions in Zhejiang Province and has expanded its reach to cover all secondary and above private hospitals, enhancing its market presence [48]. - The company is actively exploring new business models in internet healthcare and mobile medical projects, enhancing its retail network across the province [50]. Operational Efficiency and Logistics - The company has established six modern logistics centers in Zhejiang Province, creating a comprehensive supply network that ensures emergency supplies can be delivered within 4 hours and regular supplies by the next day [46]. - The company is focusing on enhancing its logistics capabilities through the integration of cold chain transportation networks, ensuring efficient and reliable delivery of medical supplies [47]. - The logistics segment improved service capabilities, with average order fulfillment time and on-time delivery rates showing steady improvement [56]. - The company is committed to building a comprehensive logistics information service platform to provide high-quality pharmaceutical logistics services to its clients [46]. - The company is leveraging digital transformation to enhance its operational efficiency, integrating online and offline services to improve overall service capabilities in the pharmaceutical distribution sector [38]. Research and Development - Research and development expenses increased by 50.97% to ¥12,929,044.94 compared to ¥8,564,100.98 in the previous year [75]. - The number of R&D personnel increased by 41.38% to 41, up from 29 in the previous year [77]. - The R&D expenditure as a percentage of operating income rose to 0.04% from 0.03% in the previous year [77]. - Investment in R&D has increased by 30%, focusing on innovative drug development and technology integration [135]. Governance and Management - The company ranked 4th in the 2022 Zhejiang listed companies' internal control index, indicating strong internal management capabilities [53]. - The company is committed to improving its governance structure and modernizing its governance capabilities to support business development [109]. - The management team consists of experienced individuals, with an average age of 45 years, indicating a blend of youth and experience [127]. - The company is focused on maintaining strong governance with independent directors and a diverse management team [128]. - The company’s management team includes key personnel such as Xu Jie, who holds 246,000 shares after a recent increase of 41,000 shares due to the capital distribution plan [127]. Strategic Initiatives - The company aims to enhance its market share and brand influence through a comprehensive organizational restructuring and integration strategy [60]. - The company is committed to high-quality development and has initiated a three-year action plan to support common prosperity [179]. - The company aims to become "China's most outstanding pharmaceutical health comprehensive service provider" and contribute to the construction of "Healthy Zhejiang" and "Healthy China" [104]. - The strategic path includes "internal growth, external expansion, integrated enhancement, innovative development, and ecosystem collaboration" to enhance competitiveness and innovation [105]. - The company is expanding its cross-border e-commerce business and establishing a new distribution system for international sales [115]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements related to development strategies and future plans [5]. - The company faces risks from frequent medical reform policies and market environment changes, which may impact the pharmaceutical distribution industry [110]. - The company emphasizes quality management and compliance to mitigate risks related to drug quality and safety [111]. - The company has established a dual prevention system for safety risk management and hazard identification, enhancing its safety standards [63]. Community Engagement and Social Responsibility - The company donated 300,000 yuan to support local agricultural projects, enhancing villagers' annual income and improving living standards [181]. - The company provided rent reductions totaling over 1.45 million yuan to more than 60 tenants in response to pandemic control policies [180]. - The company established over 90 "medicine delivery service points" and 20 "public health service stations" to enhance healthcare accessibility in remote areas [179]. - The company is actively involved in the "Rongyao and Common" health industry brand initiative, promoting health culture in rural areas [181]. Shareholder Engagement - The company held its annual general meeting with a participation rate of 60.64% and disclosed resolutions on May 12, 2022 [126]. - The company conducted two temporary shareholder meetings in July and November 2022, both with a participation rate of 60.64% [126]. - The company has a strategy to enhance shareholder value through share distribution, reflecting a commitment to returning capital to investors [128]. - The management team is committed to transparency and regular communication with shareholders regarding performance and strategic initiatives [128].